Immunic CSO hails "great" progress with MS program | News Direct

Immunic CSO hails "great" progress with MS program

Immunic Inc
News release by Immunic Inc

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | October 24, 2023 07:51 AM Eastern Daylight Time


Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some of the main talking points from the event, noting keen interest in forms of multiple sclerosis (MS) not characterised by relapses and saying that for Immunic, the most important was the focus on biomarkers.

Shortly ahead of the conference Immunic had disclosed interim data from their phase two clinical study on progressive MS, revealing a significant decrease in neurofilament light chain compared to a placebo. Additionally, the company presented data from a phase two study in Relapsing Multiple Sclerosis (RMS), indicating promising results with only a 5.8% confirmed disability worsening rate.

She concludes by saying that the company's MS program is going "great" overall, and expresses optimism about the direction of the company's research, emphasising the connection between their preclinical work and promising clinical trials outcomes.


Contact Details


Proactive United States


+1 347-449-0879

project media


HealthMedicineMSDrug DevelopmentBiotechPharmaBioPharma